glp 1 agonist oral drugs GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Orforglipron, an Oral Small-Molecule GLP-1

If you have diabetes, talk to your doctor about which medicine is right for you

16 Using the Danish nationwide registries, the purpose of this paper was to (1) compare the 1year risk of addon glucoselowering therapy and nonadherence among patients with prediabetes (HbA1c 4247 mmol/mol) or diabetes (HbA1c 48 mmol/mol) in firstline treatment with GLP1 RA or metformin

1, 2 GLP-1 drugs build on this idea, but they act on multiple pathways at once, making them a potentially more powerful approach

The primary mechanism of action involves stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and promoting satiety through central nervous system pathways

And they act on the brain's appetite centers, reducing hunger and food cravings